Cogent Biosciences, Inc.(COGT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
COGT Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Cogent Biosciences, Inc. (COGT), a Healthcare sector company. COGT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Cogent Biosciences, Inc. reports net income of $-96.4M, free cash flow of $-77.6M. Top institutional holders of COGT by reported 13-F value include FMR, BlackRock, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. COGT trades on the Nasdaq exchange and files with the SEC under CIK 1622229. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COGT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cogent Biosciences, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-96.4M
Free Cash Flow
Q2 2026
$-77.6M
ROIC
Q2 2026
-54.3%
D/E Ratio
Q2 2026
0.42
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-28.6% YoYOperating Income
-20.8% YoYEPS (Diluted)
-11.3% YoYTotal Assets
+185.9% YoYTotal Debt
Op. Cash Flow
-27.3% YoYFree Cash Flow
-27.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $7.9M |
| Net Income | $-328.9M -28.6% | $-255.9M -33.0% | $-192.4M -37.2% | $-140.2M -94.0% | $-72.3M +3.4% | $-74.8M |
| Operating Income | $-333.4M -20.8% | $-275.9M -32.6% | $-208.1M -40.8% | $-147.8M -95.7% | $-75.6M +8.1% | $-82.2M |
| EPS (Diluted) | $-2.16 -11.3% | $-1.94 +0.0% | $-1.94 -12.1% | $-1.73 +7.5% | $-1.87 | — |
| Total Assets | $937.6M +185.9% | $327.9M +4.6% | $313.4M +4.2% | $300.8M +29.6% | $232.1M -7.5% | $250.9M |
| Total Debt | $222.9M | $0.00 | — | — | — | — |
| Operating Cash Flow | $-264.4M -27.3% | $-207.8M -35.3% | $-153.6M -29.5% | $-118.6M -101.9% | $-58.8M -63.9% | $-35.9M |
| Free Cash Flow | $-266.0M -27.7% | $-208.4M -33.2% | $-156.4M -24.6% | $-125.5M -107.5% | $-60.5M | — |
Get alerted when COGT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cogent Biosciences, Inc. including:
Top Institutional Holders of COGT
FMR LLC
$993.9M25,681,174 shBlackRock, Inc.
$671.5M17,352,646 shVANGUARD PORTFOLIO MANAGEMENT LLC
$312.4M8,072,411 shVANGUARD CAPITAL MANAGEMENT LLC
$286.9M7,412,330 shSTATE STREET CORP
$269.5M6,964,919 shJupiter Topco LLC
$256.4M6,624,848 shFairmount Funds Management LLC
$213.0M5,503,418 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$193.7M5,006,104 shTCG Crossover Management, LLC
$187.9M4,854,436 shPRICE T ROWE ASSOCIATES INC /MD/
$180.1M4,652,727 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $993.9M | 25,681,174 |
| BlackRock, Inc. | $671.5M | 17,352,646 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $312.4M | 8,072,411 |
| VANGUARD CAPITAL MANAGEMENT LLC | $286.9M | 7,412,330 |
| STATE STREET CORP | $269.5M | 6,964,919 |
| Jupiter Topco LLC | $256.4M | 6,624,848 |
| Fairmount Funds Management LLC | $213.0M | 5,503,418 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $193.7M | 5,006,104 |
| TCG Crossover Management, LLC | $187.9M | 4,854,436 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $180.1M | 4,652,727 |
More Healthcare Companies
View all Healthcare →Put COGT on your watchlist
Track score changes the day Cogent Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is COGT a good stock to buy?
13F Pro's AI-powered analysis of Cogent Biosciences, Inc. (COGT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COGT are available on the COGT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. COGT is classified as a mid company.
Which hedge funds own COGT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COGT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cogent Biosciences, Inc.'s investment landscape.